Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial

Purpose: We report the intracranial efficacy of selpercatinib, a highly potent and selective RET inhibitor, approved in the United States for RET fusion-positive non–small cell lung cancers (NSCLC). Patients and Methods: In the global phase 1/2 LIBRETTO-001 trial ([NCT03157128][1]) in advanced RET -altered solid tumors, selpercatinib was dosed orally (160 mg twice every day) in 28-day cycles….

Read the full article here

Related Articles